Skip to main content
SpringerLink
Log in

Antibiotic Use in Crohn’s Disease

Why and How?

  • Review Article
  • Immunological Disorders
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

On the assumption that bacteria in the gut may be a cause of symptoms and/or complications of Crohn’s disease, various antibiotics are efficaciously employed in some affected patients. However, we do not know exactly why and how they are helpful. A possible explanation is that one or several bacterial species may have a primary role in the aetiology of Crohn’s disease, but this is not supported by the data in our possession. Another hypothesis is that intestinal bacteria may cause flare-up of the disorder, either by inducing intestinal lesions or by an interaction with the immune system, but we know today that specific pathogens can cause flares only in a minority of cases. On the contrary, there is considerable evidence that the intestinal microflora and its products may amplify and perpetuate inflammation in Crohn’s disease.

Despite the fact that few controlled trials have been conducted, and have shown inconclusive results, antibiotics are widely employed for improving symptoms and for inducing remission of active phases. At present, a combination of metronidazole and ciprofloxacin, active against many enteric bacteria, has proved to be effective in the treatment of Crohn’s disease complications. This therapy also seems to be effective in acute flares as an alternative to, or in combination with, corticosteroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Summers RW, Switz DM, Sessions Jr JT, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847–69

    PubMed  CAS  Google Scholar 

  2. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91(3): 423–33

    PubMed  CAS  Google Scholar 

  3. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn’s ileitis? J Clin Gastroenterol 1993; 17(3): 235–7

    Article  PubMed  CAS  Google Scholar 

  4. Prantera C, Kohn A, Zannoni F, et al. Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn’s disease: results of an open study. J Clin Gastroenterol 1994; 19(1): 79–88

    Article  PubMed  CAS  Google Scholar 

  5. Paulley JW. A case of Whipple’s disease (intestinal lipodystrophy). Gastroenterology 1952; 22: 128–33

    PubMed  CAS  Google Scholar 

  6. Mollin DR, Booth CC. Tropical sprue and megaloblastic anaemia. In: Wellcome Trust, editor. Wellcome Trust Collaborative Study, 1961–1969. Baltimore: Williams & Wilkins, 1971: 293–310

    Google Scholar 

  7. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995; 122: 81–9

    PubMed  CAS  Google Scholar 

  8. Kloppenburg M, Breedveld FC, Terwiel JP, et al. Minocycline in active rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1994; 37: 629–36

    Article  PubMed  CAS  Google Scholar 

  9. Langevitz P, Bank I, Zemer D, et al. Treatment of resistant rheumatoid arthritis with minocycline: an open study. J Rheumatol 1992; 19: 1502–4

    PubMed  CAS  Google Scholar 

  10. Lichtman SN, Wang J, Sartor RB, et al. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: role of cytokines, bacteria and bacterial polymers. Infect Immun 1995; 63: 2295–301

    PubMed  CAS  Google Scholar 

  11. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328–32

    PubMed  CAS  Google Scholar 

  12. Paulus HE. Minocycline treatment of rheumatoid arthritis. Ann Intern Med 1995; 122: 147–8

    PubMed  CAS  Google Scholar 

  13. Rutgeerts P, Ghoos Y, Van Trappen G, et al. Ileal dysfunction and bacterial overgrowth in patients with Crohn’s disease. Eur J Clin Invest 1981; 11: 199–206

    Article  PubMed  CAS  Google Scholar 

  14. Sherman PM. Bacterial overgrowth. In: Yamada T, editor. Textbook of gastroenterology. New York: JB Lippincott, 1991: 1530–9

    Google Scholar 

  15. Burman JH, Thompson H, Cooke WT, et al. The effects of diversion of intestinal contents on the progress of Crohn’s disease of the large bowel. Gut 1971; 12: 11–5

    Article  PubMed  CAS  Google Scholar 

  16. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 1991; 338: 771–4

    Article  PubMed  CAS  Google Scholar 

  17. Marion JF, Lachman P, Greenstein AJ, et al. Rarity of fistulas in Crohn’s disease of the jejunum. Inflamm Bowel Dis 1995; 1: 34–6

    Article  Google Scholar 

  18. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perianal Crohn’s disease with metronidazole. Gastroenterology 1980; 79: 357–65

    PubMed  CAS  Google Scholar 

  19. Brandt LJ, Bernstein LH, Boley SS, et al. Metronidazole therapy for perianal Crohn’s disease: a follow-up study. Gastroenterology 1982; 83: 383–7

    PubMed  CAS  Google Scholar 

  20. Allan A, Keighley M. Management of perianal Crohn’s disease. World J Surg 1988; 12: 198–202

    Article  PubMed  CAS  Google Scholar 

  21. Turunen U, Farkkila M, Valtonen V, et al. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease [abstract]. Gastroenterology 1993; 104: A793

    Google Scholar 

  22. Jakobovitis J, Shuster M. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984; 79: 533–40

    Google Scholar 

  23. Chiodini RJ, Van Kruiningen HJ, Merkal RS, et al. Ruminant paratuberculosis (Johne’s disease): the current status and future prospects. Cornell Vet 1984; 74: 218–62

    PubMed  CAS  Google Scholar 

  24. Morgan KL. Johne’s and Crohn’s: chronic inflammatory bowel diseases of infectious aetiology? Lancet 1987; II: 1017–9

    Article  Google Scholar 

  25. Schneebaum CW, Novick DM, Chabon AB, et al. Terminal ileitis associated with Mycobacterium avium intracellular infection in a homosexual man with acquired immunodeficiency syndrome. Gastroenterology 1987; 92: 1127–32

    PubMed  CAS  Google Scholar 

  26. Gray JR, Rabeneck L. Atypical mycobacterial infection of the gastrointestinal tract in AIDS patients. Am J Gastroenterol 1989; 84: 1521–4

    PubMed  CAS  Google Scholar 

  27. Mayberry JF, Rhodes J, Heatley RV. Infections which cause ileocolic disease in animals: are they relevant to Crohns disease? Gastroenterology 1980; 78: 1080–4

    PubMed  CAS  Google Scholar 

  28. Sutherland LR. Different patterns of Crohn’s disease. In: Prantera C, Korelitz BI, editors. Crohn’s disease. New York: Marcel Dekker, 1996: 201–15

    Google Scholar 

  29. Prantera C, Berto E, Scribano ML. Mycobacteria and subgroups of patients in Crohn’s disease. Ital J Gastroenterol 1991; 23: 49–51

    PubMed  CAS  Google Scholar 

  30. Van Kruiningen HJ, Colombel JF, Cartun RW, et al. An in-depth study of Crohn’s disease in two French families. Gastroenterology 1993; 104: 351–60

    PubMed  Google Scholar 

  31. Allan RN, Pease P, Ibbotson JP. Clustering of Crohn’s disease in a Cotswold village. Q J Med 1986; 59: 473–8

    PubMed  CAS  Google Scholar 

  32. Vantrappen G, Agg HO, Ponette E, et al. Yersinia enteritis and enterocolitis: gastroenterological aspects. Gastroenterology 1977; 72: 220–7

    PubMed  CAS  Google Scholar 

  33. Elliott PR, Forsey T, Darougar S, et al. Chlamydiae and inflammatory bowel disease. Gut 1981; 22: 25–7

    Article  PubMed  CAS  Google Scholar 

  34. Willoughby JMT, Rahman AFM, Gregory MM. Chronic colitis after Aeromonas infection. Gut 1989; 30: 686–90

    Article  PubMed  CAS  Google Scholar 

  35. Roskell DE, Hyde GM, Campbell AP, et al. HIV associated cytomegalovirus colitis as a mimic of inflammatory bowel disease. Gut 1995; 37: 148–50

    Article  PubMed  CAS  Google Scholar 

  36. Liu Y, Van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohns disease. Gastroenterology 1995; 108: 1396–404

    Article  PubMed  CAS  Google Scholar 

  37. Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol 1996; 12: 327–33

    Article  Google Scholar 

  38. Brown WR. Listeria: the latest putative pathogenetic microorganism in Crohns disease. Gastroenterology 1995; 108: 1589–90

    Article  PubMed  CAS  Google Scholar 

  39. Chiodini RJ, Van Kruiningen HJ, Merkal RS, et al. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn’s disease. J Clin Microbiol 1984; 20: 966–71

    PubMed  CAS  Google Scholar 

  40. Chiodini RJ, Van Kruiningen HJ, Thayer WR, et al. Possible role of mycobacteria in inflammatory bowel disease: I. An unclassified Mycobacterium species isolated from patients with Crohn’s disease. Dig Dis Sci 1984; 29: 1073–9

    Article  PubMed  CAS  Google Scholar 

  41. Thayer WR, Coutu JA, Chiodini RJ, et al. Possible role of mycobacteria in inflammatory bowel disease: II. Mycobacterial antibodies in Crohn’s disease. Dig Dis Sci 1984; 29: 1080–5

    Article  PubMed  Google Scholar 

  42. Chiodini RJ, Van Kruiningen HJ, Thayer WR, et al. Spheroplastic phase of Mycobacteria isolated from patients with Crohns disease. J Clin Microbiol 1986; 24: 357–63

    PubMed  CAS  Google Scholar 

  43. Elsaghier A, Prantera C, Moreno C, et al. Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn’s disease. Clin Exp Immunol 1992; 90: 503–8

    Article  PubMed  CAS  Google Scholar 

  44. Elsaghier A, Prantera C, Bothamley G, et al. Disease association of antibodies to human and mycobacterial hsp 70 and hsp 60 stress proteins. Clin Exp Immunol 1992; 89: 305–9

    Article  PubMed  CAS  Google Scholar 

  45. Cho SN, Brennan PJ, Yoshimura HH, et al. Mycobacterial aetiology of Crohn’s disease: serologic study using common my-cobacterial antigens and a species-specific glycolipid antigen from Mycobacterium paratuberculosis. Gut 1986; 27: 1353–6

    Article  PubMed  CAS  Google Scholar 

  46. Graham DY, Markesich DC, Yoshimura HH. Mycobacteria and inflammatory bowel disease: results of culture. Gastroenterology 1987; 92: 436–42

    PubMed  CAS  Google Scholar 

  47. Butcher PD, McFadden JJ, Hermon-Taylor J. Investigation of mycobacteria in Crohn’s disease tissue by Southern blotting and DNA hybridization with cloned mycobacterial genomic DNA probes from a Crohn’s disease isolated mycobacteria. Gut 1988; 29: 1222–8

    Article  PubMed  CAS  Google Scholar 

  48. Kobayashi K, Blaser MJ, Brown WR. Immunohistochemical examination for mycobacteria in intestinal tissues from patients with Crohn’s disease. Gastroenterology 1989; 96: 1009–15

    PubMed  CAS  Google Scholar 

  49. Stainsby KL, Lowes JR, Allan RN, et al. Antibodies to Mycobacterium paratuberculosis and nine species of environmental mycobacteria in Crohn’s disease and control subjects. Gut 1993; 34: 371–4

    Article  PubMed  CAS  Google Scholar 

  50. Van Kruiningen HJ, Chiodini RJ, Thayer WR, et al. Experimental disease in infant goats induced by a mycobacterium isolated from a patient with Crohn’s disease: a preliminary report. Dig Dis Sci 1986; 31: 1351–60

    Article  PubMed  Google Scholar 

  51. Bradford Hill A. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295–300

    Google Scholar 

  52. Glynn JR. A question of attribution. Lancet 1993; 342: 530–2

    Article  PubMed  CAS  Google Scholar 

  53. Ward M, McManus JPA. Dapsone in Crohn’s disease. Lancet 1975; I: 1236–7

    Article  Google Scholar 

  54. Warren JB, Rees HC, Cox TM. Remission of Crohn’s disease with tuberculosis chemotherapy. N Engl J Med 1986; 314: 182

    Article  PubMed  CAS  Google Scholar 

  55. Schultz MG, Rieder HL, Hersh T, et al. Remission of Crohn’s disease with antimycobacterial chemotherapy. Lancet 1987; II: 1391–2

    Article  Google Scholar 

  56. Prantera C, Argentieri R, Mangiarotti R, et al. Dapsone and remission of Crohn’s disease. Lancet 1988; II: 536

    Article  Google Scholar 

  57. Prantera C, Bothamley G, Levenstein S, et al. Crohn’s disease and mycobacteria: two cases of Crohn’s disease with high antimycobacterial antibody levels cured by dapsone therapy. Biomed Pharmacother 1989; 43: 295–9

    Article  PubMed  CAS  Google Scholar 

  58. Paris JC, Simon V, Paris J. Etude critique des effects de la medication antituberculeuse dans une série de 52 cas de formes sévères de la maladie de Crohn. Ann Gastroentérol Hepatol (Paris) 1977; 13: 427–33

    Google Scholar 

  59. Toulet J, Rousselet J, Viteau M. La rifampicine dans le traitement de la maladie de Crohn. Gastroenterol Clin Biol 1979; 3: 209–11

    PubMed  CAS  Google Scholar 

  60. Elliot PR, Burnham WR, Berghouse LM, et al. Sulphadoxinepyrimethamine therapy in Crohn’s disease. Digestion 1982; 23: 132–4

    Article  Google Scholar 

  61. Burnham WR, Lennard-Jones JE, Stanford JL, et al. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 1978; 2: 693–6

    Article  PubMed  CAS  Google Scholar 

  62. Shaffer JL, Hughes S, Linaker BD, et al. Controlled trial of rifampicin and ethambutol in Crohn’s disease. Gut 1984; 25: 203–5

    Article  PubMed  CAS  Google Scholar 

  63. Hampson SJ, Parker MC, Saverymuttu SH, et al. Quadruple antimycobacterial chemotherapy in Crohns disease: results at 9 months of a pilot study in 20 patients. Aliment Pharmacol Ther 1989; 3: 343–52

    Article  PubMed  CAS  Google Scholar 

  64. Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn’s disease. Gut 1994; 35: 363–8

    Article  PubMed  CAS  Google Scholar 

  65. Best WR, Bektel JM, Singleton JW, et al. Development of a Crohns Disease Activity Index: National Cooperative Crohns Disease Study. Gastroenterology 1976; 70: 439–44

    PubMed  CAS  Google Scholar 

  66. Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn’s disease. Clofazimine versus placebo. Dig Dis Sci 1991; 36: 449–53

    Article  PubMed  CAS  Google Scholar 

  67. Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513–8

    PubMed  CAS  Google Scholar 

  68. Pines AE, Cosnes J, Carbonnel F, et al. Le lamprene dans les localisations ano-perineales de la maladie de Crohn: un etude retrospective. Ann Gastroenterol Hepatol (Paris) 1993; 29: 155–63

    CAS  Google Scholar 

  69. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohns disease following therapy for Mycobacterium paratuberculosis [abstract]. Gastroenterology 1995; 108: A826

    Article  Google Scholar 

  70. Rutgeerts P, Geboes K, Vantrappen G, et al. Rifabutin and ethambutol do not help recurrent Crohn’s disease in the neoterminal ileum. J Clin Gastroenterol 1992; 15: 24–8

    Article  PubMed  CAS  Google Scholar 

  71. Basilisco G, Ranzi T, Campanini C, et al. Controlled trial of rifabutin in Crohn’s disease. Curr Ther Res 1989; 46: 242–50

    Google Scholar 

  72. Prantera C. Comment to: the role of antibiotics in Crohn’s disease. In: Prantera C, Korelitz BI, editors. Crohn’s disease. New York: Marcel Dekker, 1996: 411–2

    Google Scholar 

  73. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S116–28

    PubMed  CAS  Google Scholar 

  74. LaMont JT, Trnka YM. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet 1980; I: 381–3

    Article  Google Scholar 

  75. Newman A, Lampert JR. Campylobacter jejuni causing flare-up in inflammatory bowel disease. Lancet 1980; II: 919

    Article  Google Scholar 

  76. Skirrow MB. Campylobacter, Salmonella, Shigella and other acute bacterial disorders. In: Allan RN, Keighley MRB, Alexander-Williams J, et al., editors. Inflammatory bowel disease. Edinburgh: Churchill Livingstone, 1983: 595–607

    Google Scholar 

  77. Seaver RL. Screening for Clostridium difficile in chronic inflammatory bowel disease in relapse: is it helpful? is it cost efficient? J Clin Gastroenterol 1986; 8: 397–400

    Article  PubMed  CAS  Google Scholar 

  78. Ambrose NS, Allan RN, Keighley MRB, et al. Antibiotic therapy for treatment in relapse of intestinal Crohns disease: a prospective randomized study. Dis Colon Rectum 1985; 28: 81–5

    Article  PubMed  CAS  Google Scholar 

  79. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse in chronic bowel disease. Gastroenterology 1981; 80: 693–6

    PubMed  CAS  Google Scholar 

  80. Sartor RB. Role of intestinal microflora in initiation and perpetuation of inflammatory bowel disease. Can J Gastroenterol 1990; 4(7): 271–7

    Google Scholar 

  81. Horing E, Gopfert D, Schroter G, et al. Frequency and spectrum of microorganisms isolated from biopsy specimens in chronic colitis. Endoscopy 1991; 23: 325–7

    Article  PubMed  CAS  Google Scholar 

  82. Weber P, Koch M, Heizmann WR, et al. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992; 14(4): 302–8

    Article  PubMed  CAS  Google Scholar 

  83. Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 1981; 80: 697–700

    PubMed  CAS  Google Scholar 

  84. Kirschner BS. Does acute infection trigger chronic inflammation in pediatric patients with chronic inflammatory bowel disease? Gastroenterology 1993; 104: A725

    Google Scholar 

  85. Blaser MJ, Miller RA, Lacher J, et al. Patients with active Crohn’s disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984; 87: 888–94

    PubMed  CAS  Google Scholar 

  86. Kangro HO, Chong SKF, Hardiman A, et al. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990; 98: 549–53

    PubMed  CAS  Google Scholar 

  87. Blumberg RS. Relapse of chronic inflammatory bowel disease: ‘a riddle wrapped in a mystery inside an enigma’. Gastroenterology 1990; 98: 792–6

    PubMed  CAS  Google Scholar 

  88. Ambrose NS, Johnson M, Burdon DW, et al. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn’s disease surgery. Br J Surg 1984; 71: 623–5

    Article  PubMed  CAS  Google Scholar 

  89. Berg RD. Bacterial translocation from the gastrointestinal tract. J Med 1992; 23: 217–44

    PubMed  CAS  Google Scholar 

  90. Spaeth G, Specian RD, Berg RD, et al. Bulk prevents bacterial translocation induced by the oral administration of total parenteral nutrition solution. J Parent Enter Nutr 1990; 14: 442–7

    Article  CAS  Google Scholar 

  91. Shou J, Lappin J, Minuard EA, et al. Total parenteral nutrition, bacterial translocation and host immune function. Am J Surg 1994; 167: 134–50

    Article  Google Scholar 

  92. Prizont R, Hersh T, Floch MH. Jejunal bacterial flora in chronic small bowel disease. Am J Clin Nutr 1970; 23: 1602–7

    PubMed  CAS  Google Scholar 

  93. Beeken WL, Kanich RE. Microbial flora of the upper small bowel in Crohn’s disease. Gastroenterology 1973; 65: 390–7

    PubMed  CAS  Google Scholar 

  94. Ursing B, Kamme C. Metronidazole for Crohn’s disease. Lancet 1975; I: 775–7

    Article  Google Scholar 

  95. Bockus HL. Regional enteritis. In: Gastroenterology. Vol. 2, sect V. Philadelphia: W.B. Saunders, 1976: 574–8

    Google Scholar 

  96. Videla S, Vilaseca J, Salas A, et al. Key role of intestinal microflora in sustaining chronic inflammation of the rat colon. Gastroenterology 1993; 104: A797

    Google Scholar 

  97. Abreu MT, Targan SR. The future of Crohns disease: new developments in etiopathogenesis and therapeutics. In: Prantera C, Korelitz BI, editors. Crohns disease. New York: Marcel Dekker, 1996: 561–86

    Google Scholar 

  98. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn’s disease and their relatives: a possible etiologic factor. Ann Intern Med 1986; 105: 883–5

    PubMed  CAS  Google Scholar 

  99. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993; 341: 1437–9

    Article  PubMed  CAS  Google Scholar 

  100. Keighley MRB, Arabi Y, Dimock F, et al. Influence of inflammatory bowel disease on intestinal microflora. Gut 1978; 19: 1099–104

    Article  PubMed  CAS  Google Scholar 

  101. Wensinck F, Custers van Lieshoout LMC, Poppelaars Kustermans PAJ, et al. The faecal flora of patients with Crohn’s disease. J Hyg Camb 1981; 87(1): 1–12

    Article  PubMed  CAS  Google Scholar 

  102. Van De Merwe JR, Schroder AM, Wensinck F, et al. The obligate anaerobic faecal flora of patients with Crohn’s disease and their first-degree relatives. Scand J Gastroenterol 1988; 23: 1125–31

    Article  PubMed  Google Scholar 

  103. Burke DA, Axon ATR. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 1988; 297: 102–4

    Article  PubMed  CAS  Google Scholar 

  104. Tabaqchali S, O’Donoghue DP, Bettelheim KA. Escherichia coli antibodies in patients with inflammatory bowel disease. Gut 1978; 19: 108–13

    Article  PubMed  CAS  Google Scholar 

  105. Brown WR, Lee E. Radioimmunological measurements of bacterial antibodies: II. Human serum antibodies reactive with Bacteroides fragilis and enterococcus in gastrointestinal and immunological disorders. Gastroenterology 1974; 66: 1145–53

    PubMed  CAS  Google Scholar 

  106. Macpherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38: 365–75

    Article  PubMed  CAS  Google Scholar 

  107. Fiocchi C. Overview of inflammatory bowel disease pathogenesis. Can J Gastroenterol 1990; 4: 309–16

    Google Scholar 

  108. Gardiner KR, Halliday MI, Barclay GR, et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897–901

    Article  PubMed  CAS  Google Scholar 

  109. Hudson MJ, Hill MJ, Elliot PR, et al. The microbial flora of the rectal mucosa and faeces of patients with Crohn’s disease before and during antimicrobial chemotherapy. J Med Microbiol 1984; 18: 335–45

    Article  PubMed  CAS  Google Scholar 

  110. Saverymuttu S, Hodgson HJF, Chadwick VS. Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn’s disease. Gut 1985; 26: 994–8

    Article  PubMed  CAS  Google Scholar 

  111. Moss AA, Carbone JV, Kressel HY. Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn’s disease. Am J Roentgenol 1978; 1331: 787–90

    Google Scholar 

  112. Dickinson RJ, O’Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380–4

    Article  PubMed  CAS  Google Scholar 

  113. Danzi JT. Trimethoprim-sulphamethoxazole therapy of inflammatory bowel disease [abstract]. Gastroenterology 1989; 96: A110

    Google Scholar 

  114. Gradon JD, Zimbalist EH. Is trimethoprim-sulfamethoxazole helpful in Crohn’s disease? J Clin Gastroenterol 1990; 12: 598–607

    Article  PubMed  CAS  Google Scholar 

  115. Blichfeldt P, Blomhoff JP, Myhre E, et al. Metronidazole in Crohn’s disease: a double blind cross-over clinical trial. Scand J Gastroenterol 1978; 13: 123–7

    Article  PubMed  CAS  Google Scholar 

  116. Rosen A, Ursing B, Alm T, et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the Cooperative Crohn’s Disease Study in Sweden: I. Design and methodologic considerations. Gastroenterology 1982; 83: 541–9

    PubMed  CAS  Google Scholar 

  117. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: the Cooperative Crohn’s Disease Study in Sweden: II. Result. Gastroenterology 1982; 83: 550–62

    PubMed  CAS  Google Scholar 

  118. Meyers S, Janowitz HD. ‘Natural history’ of Crohn’s disease: an analytic review of the placebo lesson. Gastroenterology 1984; 87: 1189–92

    PubMed  CAS  Google Scholar 

  119. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut 1991; 32: 1071–5

    Article  PubMed  CAS  Google Scholar 

  120. Bernstein CN, Shanahan F. Metronidazole in Crohn’s disease: what’s the score? Gastroenterology 1992; 102: 1435–6

    PubMed  CAS  Google Scholar 

  121. Goldman P. Metronidazole. N Engl J Med 1980; 303: 1212–8

    Article  PubMed  CAS  Google Scholar 

  122. Krook A, Lindstrom B, Kjellander J, et al. Relation between concentrations of metronidazole and Bacteroides sp. in faeces of patients with Crohn’s disease and healthy individuals. J Clin Pathol 1981; 34: 645–50

    Article  PubMed  CAS  Google Scholar 

  123. Gorbach SL. Viral infections and inflammatory bowel disease. Gastroenterology 1982; 83: 1318–9

    Google Scholar 

  124. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 1995; 108: 1617–21

    Article  PubMed  CAS  Google Scholar 

  125. Margolis PS, Thayer WR. The role of antibiotics in Crohn’s disease. In: Prantera C, Korelitz BI, editors. Crohn’s disease. New York: Marcel Dekker, 1996: 401–12

    Google Scholar 

  126. Bradley WG, Karlsson IJ, Rassol CG. Metronidazole neuropathy. BMJ 1977; 3: 610–1

    Article  Google Scholar 

  127. Duffy L, Daum F, Fisher S, et al. Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterology 1985; 88: 681–4

    PubMed  CAS  Google Scholar 

  128. Rustia M, Shubik P. Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Natl Cancer Inst 1972; 48: 721–9

    PubMed  CAS  Google Scholar 

  129. Nord CE. Effect of quinolones on the human intestinal microflora. Drugs 1995; 49 (Suppl. 2): 81–5

    Article  PubMed  CAS  Google Scholar 

  130. Sanders CC, Sanders WE, Goerging RV. Overview of preclinical studies with ciprofloxacin. Am J Med 1987; 82: 2–11

    Article  PubMed  CAS  Google Scholar 

  131. Norel CE. Effect of new quinolones on the human gastrointestinal microflora. Rev Infect Dis 1988; 10 (Suppl. 1): 5193–6

    Google Scholar 

  132. Brumfitt W, Franklin I, Grady D, et al. Changes in the pharmacokinetics of ciprofloxacin and faecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984; 26: 757–61

    Article  PubMed  CAS  Google Scholar 

  133. Chiodini RJ. Bacterial activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis. Antimicrob Agents Chemother 1990; 34: 366–7

    Article  PubMed  CAS  Google Scholar 

  134. Pichler HET, Diridl G, Stickler K, et al. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 1987; 82 (Suppl. 4A): 329–32

    PubMed  CAS  Google Scholar 

  135. Ericsson CD, Johnson PC, Dupont HL, et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers’ diarrhea: a placebo-controlled, randomized trial. Ann Intern Med 1987; 106: 216–20

    PubMed  CAS  Google Scholar 

  136. Taylor DN, Sanchez JL, Candler W, et al. Treatment of travelers’ diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. a placebo-controlled, randomized trial. Ann Intern Med 1991; 114: 731–4

    PubMed  CAS  Google Scholar 

  137. Wolf JL. Ciprofloxacin may be useful in Crohn’s disease [abstract]. Gastroenterology 1990; 98: A212

    Google Scholar 

  138. Greenbloom SL, Steinhart AH, Greenberg GR, et al. Ciprofloxacin and metronidazole: combination antibiotic therapy for ileocolonic Crohn’s disease [abstract]. Clin Invest Med 1995; 18(A): 48

    Google Scholar 

  139. Turunen U, Farkkila M, Hakala K, et al. Ciprofloxacin treatment combined with conventional therapy in Crohn’s disease: a prospective, double blind, placebo controlled study [abstract]. Gut 1995; 37(A): 193

    Google Scholar 

  140. Katz JA, Fiocchi C. Causes and mechanisms of Crohn’s disease. In: Prantera C, Korelitz BI, editors. Crohn’s disease. New York: Marcel Dekker, 1996: 9–56

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Division, Ospedale Nuovo Regina Margherita, Via E. Morosini 30, Rome, 00153, Italy

    Cosimo Prantera, Maria Lia Scribano, Eva Berto & Fabio Zannoni

Authors
  1. Cosimo Prantera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Lia Scribano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eva Berto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fabio Zannoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prantera, C., Scribano, M.L., Berto, E. et al. Antibiotic Use in Crohn’s Disease. BioDrugs 8, 293–306 (1997). https://doi.org/10.2165/00063030-199708040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199708040-00005

Search

Navigation